Znn3bq.jpeg
²é¿´: 623  |  »Ø¸´: 9

linglingchen

Ìú³æ (СÓÐÃûÆø)


[½»Á÷] Science£º×¢ÉäÇ¿Á¦¿¹ÌåÒÖÖÆÑªÒºÖÐHIV²¡¶¾

12ÔÂ23ÈÕ£¬À´×ÔÃÀ¹úNIHµÄ¿ÆÑ§¼ÒÃÇÔÚ¹ú¼ÊѧÊõÆÚ¿¯ÉÏ·¢±íÁËÒ»Ïî×îÐÂÑо¿½øÕ¹£¬ËûÃDZ¨¸æ³Æ×¢ÉäÒ»ÖÖ½Ð×öVRC01µÄǿЧ¿¹Ìå¾ÍÄܹ»ÒÖÖÆÎ´½ÓÊÜ¿¹Äæ×ªÂ¼²¡¶¾ÖÎÁƵÄHIVЯ´øÕßѪҺÖеÄHIV²¡¶¾Ë®Æ½¡£Ñо¿ÈËÔ±»¹·¢ÏÖͨ¹ý¾²Âö×¢Éä»òƤÏÂ×¢É䷽ʽ½«VRC01¿¹Ìå×¢È벡¶¾Ð¯´øÕßÌåÄÚ¾ßÓзdz£ºÃµÄ°²È«ÐÔºÍÄÍÊÜÐÔ£¬²¢ÇÒ×¢ÈëµÄ¿¹ÌåÄܹ»ÔÚ²¡ÈËѪҺÖб£³Ö½Ï³¤Ê±¼ä¡£
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
http://stm.sciencemag.org/content/7/319/319ra206

Passive aggression for HIV

Antibodies that neutralize HIV could add to the therapeutic arsenal to prevent and treat disease. Lynch et al. have now tested one such antibody¡ªVRC01¡ªin HIV-infected individuals. Although little difference was observed in viral reservoir in individuals on antiretroviral therapy, plasma viremia was reduced in untreated subjects with a single infusion of VRC01, preferentially suppressing neutralization-sensitive strains. Passive immunization with neutralizing antibodies could therefore aid in viral suppression in HIV-infected individuals.
Abstract

Passive immunization with HIV-1¨Cneutralizing monoclonal antibodies (mAbs) is being considered for prevention and treatment of HIV-1 infection. As therapeutic agents, mAbs could be used to suppress active virus replication, maintain suppression induced by antiretroviral therapy (ART), and/or decrease the size of the persistent virus reservoir. We assessed the impact of VRC01, a potent human mAb targeting the HIV-1 CD4 binding site, on ART-treated and untreated HIV-1¨Cinfected subjects. Among six ART-treated individuals with undetectable plasma viremia, two infusions of VRC01 did not reduce the peripheral blood cell¨Cassociated virus reservoir measured 4 weeks after the second infusion. In contrast, six of eight ART-untreated, viremic subjects infused with a single dose of VRC01 experienced a 1.1 to 1.8 log10 reduction in plasma viremia. The two subjects with minimal responses to VRC01 were found to have predominantly VRC01-resistant virus before treatment. Notably, two subjects with plasma virus load <1000 copies/ml demonstrated virus suppression to undetectable levels for over 20 days until VRC01 levels declined. Among the remaining four subjects with baseline virus loads between 3000 and 30,000 copies, viremia was only partially suppressed by mAb infusion, and we observed strong selection pressure for the outgrowth of less neutralization-sensitive viruses. In summary, a single infusion of mAb VRC01 significantly decreased plasma viremia and preferentially suppressed neutralization-sensitive virus strains. These data demonstrate the virological effect of this neutralizing antibody and highlight the need for combination strategies to maintain virus suppression.
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:

²é¿´È«²¿É¢½ðÌù

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

´ósusu

Ìú³æ (СÓÐÃûÆø)


°²È«ÐÔºÍÄÍÊÜÐÔ£¬ÒѾ­½øÈëÁÙ´²ºóÆÚÁËô£¿
9Â¥2016-01-10 22:44:07
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ttshi2013

гæ (³õÈëÎÄ̳)


¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ScienceÉϵÄÎÄÕ£¬Ç°ÑØÐÔ»¹ÊDz»´íµÄ¡£
10Â¥2016-01-15 11:20:45
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¼òµ¥»Ø¸´
jiantu2Â¥
2015-12-29 10:31   »Ø¸´  
linglingchen(½ð±Ò+1): лл²ÎÓë
liangbk3Â¥
2015-12-29 11:05   »Ø¸´  
linglingchen(½ð±Ò+1): лл²ÎÓë
bit_14Â¥
2015-12-29 11:30   »Ø¸´  
linglingchen(½ð±Ò+1): лл²ÎÓë
tan9145Â¥
2015-12-29 12:10   »Ø¸´  
linglingchen(½ð±Ò+1): лл²ÎÓë
tan9146Â¥
2015-12-29 12:13   »Ø¸´  
psylhh7Â¥
2015-12-29 12:14   »Ø¸´  
linglingchen(½ð±Ò+1): лл²ÎÓë
2015-12-30 09:12   »Ø¸´  
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ linglingchen µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ±¾¿ÆÄÏ·½Ò½¿Æ´óѧ Ò»Ö¾Ô¸985 ҩѧѧ˶284·Ö Çóµ÷¼Á +5 ÈõË®ÌýÎÄ 2026-04-09 5/250 2026-04-12 13:16 by shengxi123
[¿¼ÑÐ] 295·ÖÇóµ÷¼Á +12 ?ÒªÉϰ¶? 2026-04-10 12/600 2026-04-12 12:49 by ѧzh
[¿¼ÑÐ] 293Çóµ÷¼Á +10 ÎÒ°®¸ßÊý¸ßÊý°®Î 2026-04-12 10/500 2026-04-12 11:15 by Ò»ÇÐOK
[¿¼ÑÐ] Çóµ÷¼Á +16 ÕÅzic 2026-04-05 17/850 2026-04-12 11:01 by zhouwenxian
[¿¼ÑÐ] ²ÄÁϹ¤³Ì281»¹Óе÷¼Á»ú»áÂð +24 xaw. 2026-04-11 24/1200 2026-04-12 10:32 by Öí»á·É
[¿¼ÑÐ] µç×ÓÐÅÏ¢270Çóµ÷¼Á +15 terminal469 2026-04-07 15/750 2026-04-12 09:44 by ÄæË®³Ë·ç
[¿¼ÑÐ] Çóµ÷¼Á£¬262»úеר˶ +8 àÅyyl 2026-04-08 8/400 2026-04-12 02:31 by Çï¶¹²ËÑ¿
[¿¼ÑÐ] 299Çóµ÷¼Á +8 ZVVZ13 2026-04-08 8/400 2026-04-12 00:40 by À¶ÔÆË¼Óê
[¿¼ÑÐ] µ÷¼Á +6 ÇàµÆ²»¸º 2026-04-09 6/300 2026-04-11 20:35 by dongdian1
[¿¼ÑÐ] µç×ÓÐÅÏ¢279Çóµ÷¼Á£¬ÓÐÊé¶Á¾ÍÐÐ +8 wwwooden 2026-04-08 11/550 2026-04-11 20:22 by cq2548
[¿¼ÑÐ] Çóµ÷¼Á +10 Á§ÜÔÒ»¶¨Éϰ¶ 2026-04-10 10/500 2026-04-11 13:31 by 1005715100
[¿¼ÑÐ] Ò»Ö¾Ô¸¶«±±´óѧ¿ØÖƹ¤³Ì085406Êý¶þÓ¢¶þ385£¬Çóµ÷¼Á +8 Ezra_Zhang 2026-04-09 8/400 2026-04-11 09:15 by Öí»á·É
[¿¼ÑÐ] 085800 ÄÜÔ´¶¯Á¦Çóµ÷¼Á +6 °¢biu°¡°¡°¡°¡°¡ 2026-04-10 6/300 2026-04-10 15:03 by hemengdong
[¿¼ÑÐ] Ò»Ö¾Ô¸ÏôóÉúÎïѧ332Çóµ÷¼Á +10 ³Ø³Ø³Ø³Ø³Ø³Ø 2026-04-08 10/500 2026-04-09 17:10 by ¶À×íÃι³Ç
[¿¼ÑÐ] ÇóÖú071001µ÷¼Á£¡£¡£¡ +7 »ÆÊØËÉ 2026-04-05 8/400 2026-04-09 09:07 by ÐìÁ¼°×ü´óÏÀ
[¿¼ÑÐ] »úеר˶273ÇëÇóµ÷¼Á +6 ¸ýÉêÈÉÉê 2026-04-07 6/300 2026-04-08 22:41 by bljnqdcc
[¿¼ÑÐ] »úеµ÷¼Á +3 zzzbcb 2026-04-07 3/150 2026-04-07 22:19 by hemengdong
[¿¼ÑÐ] 312Çóµ÷¼Á +18 gtw1 2026-04-06 20/1000 2026-04-07 18:16 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 085602µ÷¼Á ³õÊÔ×Ü·Ö335 +3 19123253302 2026-04-06 3/150 2026-04-07 18:00 by jp9609
[¿¼ÑÐ] Çóµ÷¼Áµ½0856²ÄÁϹ¤³Ì +3 ³Ì9915 2026-04-05 3/150 2026-04-05 18:15 by À¶ÔÆË¼Óê
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û